|
StemCells hopes a small focus will mean big business. The company discovers cell-based therapies to treat diseases of the central nervous system (CNS), such as cerebral palsy and Alzheimer's disease, as well as spinal cord injury. It is researching stem cell and progenitor cell (cells that have developed from stem cells) therapies to repair neural tissue damaged by disease and injury, and has discovered markers for CNS stem cells and a way to reproduce them for transplant. Its lead therapy candidate may treat Batten disease, a fatal genetic enzyme deficiency. In addition to its CNS research, StemCells is also studying liver cells, hoping to find treatments for diseases such as hepatitis and liver cancer.
|
| | | Contact Information | |
Address: |
3155 Porter Dr.
Palo Alto, CA 94304-1213
| | Phone: | 650-475-3100 | | Fax: | 650-475-3101 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.20 M | | Revenue Growth (1 yr): | 308.50% | | Employees (2008): | 55 | | Employee Growth (1 yr): | (-12.70%) |
|
|
Key People
| | • |
Chairman:
John J. Schwartz
| | • |
President, CEO, and Director; President, StemCells Californi:
Martin M. McGlynn
| | • |
SVP Development and Operations:
Stewart Craig
|
|
|
